

11 Sep 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a look ahead at potential oncology blockbuster approvals; strong data for Mirati's KRAS contender in colorectal cancer; Keytruda's architect reflects in its great success; Amgen's waiting game for ChemoCentryx; and a look at dynamics in China's sizzling immuno-oncology market.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 9 September 2022, including: a look ahead at potential oncology blockbuster approvals; strong data for [Mirati Therapeutics, Inc.](#)'s KRAS contender in colorectal cancer; Keytruda's architect reflects in its great success; [Amgen, Inc.](#)'s waiting game for [ChemoCentryx, Inc.](#); and a look at dynamics in China's sizzling immuno-oncology market.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Five Potential Blockbuster Oncology Approvals To Look Out For In 2023](#)" - Scrip, 6 Sep, 2022.)

(Also see "[ESMO: Mirati's Adagrasib Appears To Maintain CRC Edge In KRAS Race](#)" - Scrip, 7 Sep, 2022.)

(Also see "[Architect Of Keytruda Reflects On A Great Scientific Success Story](#)" - Scrip, 5 Sep, 2022.)

(Also see "[*Amgen Played Waiting Game Before Agreeing \\$3.7bn ChemoCentryx Deal*](#)" - Scrip, 2 Sep, 2022.)

(Also see "[*H1 Winners And Laggards In China's Sizzling Home-Grown IO market*](#)" - Scrip, 8 Sep, 2022.)

[Click here to explore this interactive content online](#) ✎